8 completed. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 5 | Completed 5 |
Follow Hyperoxaluria: new trials by email Literature Review of Hyperoxaluria trials Research Report on Hyperoxaluria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients DCR-PHXC, Sterile Normal Saline (0.9% NaCl) - Primary Hyperoxaluria Type 3 | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 6 | 2020-09-14 | 2024-09-19 |
| Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria DCR-PHXC, Placebo - Primary Hyperoxaluria | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 43 | 2017-12-06 | 2024-09-19 |
| Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 Lumasiran, Placebo - Primary Hyperoxaluria Type 1 (PH1) | Phase 1 / Phase 2 | Completed | Alnylam Pharmaceuticals | 52 | 2016-03-08 | 2020-01-30 |
| Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria Oxabact OC5 capsules, Placebo capsules - Primary Hyperoxaluria | Phase 1 / Phase 2 | Completed | OxThera | 28 | 2013-12-01 | 2015-10-16 |
| Hydroxyproline Influence on Oxalate Metabolism Hydroxyproline and Leucine - Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2013-09-01 | 2017-07-02 |
| Oxazyme in Patients With Hyperoxaluria Oxazyme - Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2010-05-01 | 2012-12-24 |
| Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Oxadrop, Agri-King Synbiotic (AKSB), Placebo - Nephrolithiasis, Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 40 | 2006-02-01 | 2012-05-31 |
| Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria C-13 labeled oxalate - Enteric Hyperoxaluria, Hyperoxaluria | Phase 1 | Completed | Mayo Clinic | 114 | 1998-12-01 | 2020-03-03 |
Hyperoxaluria, Primary (5) · Calculi (1) · Crohn Disease (1) · Kidney Calculi (1) · Nephrolithiasis (1) · Primary hyperoxaluria type 1 (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Carbohydrate Metabolism, Inborn Errors (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Metabolic Diseases (5) · Metabolism, Inborn Errors (5) · Nutritional and Metabolic Diseases (5) · Digestive System Diseases (1) · Gastroenteritis (1)
Hydroxyproline (1) · Leucine (1) · Oxalates (1) · lumasiran (1) · nedosiran (1) · oxalate decarboxylase (1)
Mayo Clinic (4) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (2) · Alnylam Pharmaceuticals (1) · OxThera (1)
United States (6) · Germany (4) · United Kingdom (4) · France (3) · Netherlands (3) · Israel (1)
John C Lieske, MD (2) · Alexandra Haagensen, MD, MBA (1) · Bernd Hoppe, MD PhD (1) · Dawn Milliner (1) · John Lieske, MD (1) · Tracy McGregor, MD, MSCI (1)
PMID 20736987, PMID 33985991, PMID 40601241, PMID 41388232
U54DK083908 (2), 2015 (1), P50DK083007 (1), R21AT002534 (1), UL1RR024150 (1)